【レポートの概要（一部）】
1. Report Overview
1.1 Global Ophthalmic Drugs Market Overview
1.2 Global Ophthalmic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. Introduction to Ophthalmic Drugs
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 The Global Burden of Eye Disease
2.3 Ophthalmic Drugs: Market Segmentation
2.4 Glaucoma: the ‘Silent Thief of Sight’
2.4.1 A Classification of Glaucoma
2.4.1.1 Primary Open-Angle Glaucoma
2.4.1.2 Acute Angle-Closure Glaucoma
2.4.1.3 Congenital Glaucoma
2.4.1.4 Secondary Glaucoma
2.4.1.5 Normal-Tension Glaucoma
2.4.1.6 Ocular Hypertension
2.4.2 Risk Factors for Glaucoma
2.4.3 Diagnosis of Glaucoma
2.4.4 Drug Treatment of Glaucoma
2.4.5 Laser Treatment and Surgery for Glaucoma
2.5 Age-Related Macular Degeneration (AMD)
2.5.1 Dry (non-exudative) AMD
2.5.2 Wet (exudative) AMD
2.5.3 Risk Factors for AMD
2.5.4 Diagnosis of AMD
2.5.5 Treatment of AMD
2.6 Diabetic Retinopathy (DR)
2.6.1 Diagnosis of Diabetic Retinopathy
2.6.2 Treatment of Diabetic Retinopathy
2.7 Ocular Allergy and Allergic Conjunctivitis
2.7.1 Diagnosis of Ocular Allergy
2.7.2 Treatment of Ocular Allergy
2.8 Ocular Inflammatory Disease
2.8.1 Treatment of Ocular Inflammatory Disease
2.9 Eye Infections
2.9.1 Treatment of Eye Infections
2.10 Dry Eye Syndrome
2.10.1 Treatment of Dry Eye Syndrome
2.11 Phases of Clinical Trials
2.12 Currency Exchange Rates in This Report
3. Ophthalmic Drugs: World Market 2015-2025
3.1 The World Ophthalmic Drugs Market in 2014
3.2 World Ophthalmic Drugs Market: Sales Forecast 2015-2025
3.3 Leading Ophthalmic Drugs
3.4 Leading Companies in the Ophthalmic Drugs Market
3.4.1 Top 25 Ophthalmic Drug Manufacturers
3.5 Ophthalmic Drugs Market Segments: Sales Forecasts 2015-2025
3.5.1 Retinal Disorders Drugs Market: Sales Forecast 2015-2025
3.5.2 Allergic, Inflammatory and Infective Drugs Market: Sales Forecast 2015-2025
3.5.3 Glaucoma Drugs Market: Sales Forecast 2015-2025
3.5.4 Dry Eye Drugs Market: Sales Forecast 2015-2025
3.5.5 Other Ophthalmic Drugs Market: Sales Forecast 2015-2025
3.6 How Will Segmental Market Shares Change to 2025?
3.7 CAGR Forecasts of Ophthalmic Drugs Markets From 2014-2025
3.8 Market Attractiveness of Ophthalmic Drugs Markets in 2019
3.9 Market Attractiveness of Ophthalmic Drugs Markets in 2025
3.10 World Ophthalmic Drugs Market: Drivers and Restraints 2015-2025
3.10.1 World Ophthalmic Drugs Market: Analysis of Drivers
3.10.2 World Ophthalmic Drugs Market: Analysis of Restraints
4. Leading US Ophthalmic Drug Manufacturers 2015-2025
4.1 Allergan Overview
4.1.1 Allergan: Ophthalmic Product Portfolio
4.1.1.1 Restasis: Generic Launch in 2015?
4.1.1.2 Restasis: Sales Forecast 2015-2025
4.1.1.3 Lumigan and Ganfort: Marketed in Over 67 Countries
4.1.1.4 Lumigan and Ganfort: Sales Forecast 2015-2025
4.1.1.5 Refresh Brand Products: the Range
4.1.1.6 Refresh Brand Products: Sales Forecast 2015-2025
4.1.1.7 Alphagan/Alphagan P and Combigan: Extended Lifecycle
4.1.1.8 Alphagan/Alphagan P and Combigan: Sales Forecast 2015-2025
4.1.1.9 Acular: New Forms Receiving FDA Approvals
4.1.1.10 Acular: Sales Forecast 2015-2025
4.1.1.11 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Oedema
4.1.2 Allergan: Ophthalmic Product Pipeline
4.1.2.1 Novadur (Intravitreal Brimonidine Implant)
4.1.2.2 AGN 208397 (Beclomethasone Intravitreal Injection)
4.1.2.3 Anti-VEGF DARPins (VEGF Inhibitors)
4.1.3 Allergan: Ophthalmic Revenue Forecast 2015-2025
4.1.3.1 Allergan: Ophthalmic Drugs Market Share Forecast 2015-2025
4.1.4 Allergan: SWOT Analysis
4.2 Merck Overview
4.2.1 Merck: Exiting the Ophthalmic Drugs Market
4.2.2 Merck: Ophthalmic Product Pipeline
4.2.3 Merck: Ophthalmic Drugs Sales in 2013 and 2014
4.3 Pfizer Overview
4.3.1 Pfizer: Ophthalmic Product Portfolio
4.3.1.1 Xalatan/Xalacom: First Ophthalmic Blockbuster
4.3.1.2 Xalatan/Xalacom: Sales Forecast 2015-2025
4.3.2 Pfizer: Ophthalmic Product Pipeline
4.3.3 Pfizer: Revenue Forecast 2015-2025
4.3.3.1 Pfizer: Ophthalmic Drugs Market Share Forecast 2015-2025
4.3.4 Pfizer: SWOT Analysis
4.4 Regeneron Overview
4.4.1 Regeneron: Ophthalmic Product Portfolio
4.4.1.1 Eylea: Superior Clinical Outcomes than Lucentis and Avastin?
4.4.1.2 Eylea: US Sales Forecast 2015-2025
4.4.2 Regeneron: Ophthalmic Product Pipeline
4.4.3 Regeneron: Revenue Forecast 2015-2025
4.4.3.1 Regeneron: Ophthalmic Drugs Market Share Forecast 2015-2025
4.4.4 FDA Approves Zaltrap (aflibercept)
4.4.5 Eylea/Zaltrap and the Davis-Smyth Patent Agreements
4.4.6 Regeneron: SWOT Analysis
4.5 Akorn Overview
4.5.1 Akorn: Ophthalmic Product Portfolio
4.5.1.1 AzaSite: AzaSite Plus and AzaSite Xtra Set to Drive AzaSite Sales
4.5.1.2 AzaSite: Sales Forecast 2015-2025
4.5.1.3 Zioptan: Acquired from Merck
4.5.1.4 Zioptan: Sales Forecast 2015-2025
4.5.1.5 Cosopt/Cosopt PF: Acquired from Merck
4.5.1.6 Cosopt/Cosopt PF: US Sales Forecast 2015-2025
4.5.2 Akorn: Revenue Forecast 2015-2025
4.5.2.1 Akorn: Ophthalmic Drugs Market Share Forecast 2015-2025
4.5.3 Akorn: SWOT Analysis
5. Leading European Ophthalmic Drug Manufacturers 2015-2025
5.1 Bayer Overview
5.1.1 Eylea: non-US Sales Forecast 2015-2025
5.1.2 Bayer: Revenue Forecast 2015-2025
5.1.2.1 Bayer: Ophthalmic Drugs Market Share Forecast 2015-2025
5.2 Novartis (including Alcon) Overview
5.2.1 Novartis: Ophthalmic Product Portfolio
5.2.1.1 Lucentis: Best-Selling Ophthalmic Drug in 2014
5.2.1.2 Lucentis: Non-US Sales Forecast 2015-2025
5.2.1.3 Travatan/Travatan Z and DuoTrav: DuoTrav Awaiting US Approval
5.2.1.4 Travatan/Travatan Z and DuoTrav: Sales Forecast 2015-2025
5.2.1.5 Vigamox: Competes with Alcon’s Moxeza
5.2.1.6 Vigamox: Sales Forecast 2015-2025
5.2.1.7 Azopt: Marketed in Major Markets
5.2.1.8 Azopt: Sales Forecast 2015-2025
5.2.1.9 Jetrea: Sales Revenues Fall Short
5.2.1.10 Jetrea: Non-US Sales Forecast 2015-2025
5.2.2 Novartis: Ophthalmic Product Pipeline
5.2.2.1 Finafloxacin (MerLion Pharmaceuticals/Novartis)
5.2.2.2 AKB 9778 (Aerpio Therapeutics)
5.2.3 Novartis: Revenue Forecast 2015-2025
5.2.3.1 Novartis: Ophthalmic Drugs Market Share Forecast 2015-2025
5.2.4 Novartis: SWOT Analysis
5.3 Roche Overview
5.3.1 Roche: Ophthalmic Product Portfolio
5.3.1.1 Lucentis: US Sales Forecast 2015-2025
5.3.1.2 Avastin: Will It Remain Off-Label Use for Wet AMD?
5.3.1.3 Avastin: Sales Forecast 2015-2025
5.3.2 Roche: Ophthalmic Product Pipeline
5.3.2.1 Lampalizumab (RG7417)
5.3.3 Roche: Revenue Forecast 2015-2025
5.3.3.1 Roche: Ophthalmic Drugs Market Share Forecast 2015-2025
5.3.4 Roche: SWOT Analysis
5.3.4.1 Lucentis Granted Fourth Approval in the US
6. Leading Asia-Pacific and Other Ophthalmic Drug Manufacturers 2015-2025
6.1 Santen Overview
6.1.1 Santen: Ophthalmic Product Portfolio
6.1.1.1 Eylea: Japan Sales Forecast 2015-2025
6.1.1.2 Hyalein: Santen’s Best Selling Drug in 2014
6.1.1.3 Hyalein: Sales Forecast 2015-2025
6.1.1.4 Cosopt: Non-US Sales Forecast 2015-2025
6.1.1.5 Tapros/Taflotan: Sales Forecast 2015-2025
6.1.1.6 Diquas: Sales Forecast 2015-2025
6.1.1.7 Cravit: Higher Concentration Showing Significant Efficacy
6.1.1.8 Cravit: Sales Forecast 2015-2025
6.1.1.9 Trusopt: Non-US Sales Forecast 2015-2025
6.1.2 Santen: Ophthalmic Product Pipeline
6.1.3 Santen: Revenue Forecast 2015-2025
6.1.3.1 Santen: Ophthalmic Drugs Market Share Forecast 2015-2025
6.1.4 Santen: SWOT Analysis
6.2 Senju Overview
6.2.1 Senju: Ophthalmic Product Portfolio
6.2.2 Senju: Ophthalmic Product Pipeline
6.2.2.1 Y 39983 (SNJ 1656)
6.2.2.2 Difluprednate (SJE-2079)
6.2.3 Senju: Revenue Forecast 2015-2025
6.2.3.1 Senju: Ophthalmic Drugs Market Share Forecast 2015-2025
6.2.4 Senju: SWOT Analysis
6.3 Valeant Overview
6.3.1 Valeant: Ophthalmic Product Portfolio
6.3.1.1 Timoptic: US Sales Forecast 2015-2025
6.3.1.2 Bromday: New Formulation Released
6.3.1.3 Bromday: Sales Forecast 2015-2025
6.3.2 Valeant: Ophthalmic Product Pipeline
6.3.2.1 Vesneo (BOL 303259-X)
6.3.2.2 MIM-D3 (tyrosine kinase receptor antagonist, Valeant)
6.3.2.3 Brimonidine for Eye Whitening (Valeant)
6.3.3 Valeant: Revenue Forecast 2015-2025
6.3.3.1 Valeant: Ophthalmic Drugs Market Share Forecast 2015-2025
6.3.4 Valeant: SWOT Analysis
6.3.4.1 Valeant’s Acquisition of Bausch and Lomb: Aggressive Expansion?
7. Emerging Ophthalmic Drug Manufacturers in 2015
7.1 Pipeline and Other Companies, 2015
7.2 Abbott: Fenofibrate Approved in Australia for Diabetic Retinopathy
7.3 Acucela
7.4 Aerie Pharmaceuticals
7.5 Aerpio Therapeutics: Developing AKB 9778
7.6 Alimera Sciences
7.6.1 Iluvien Gained Recent FDA Approval
7.6.2 NADPH Oxidase Inhibitors Offer Potential for Dry AMD
7.7 Altheos
7.8 Amakem
7.9 Ampio Pharmaceuticals
7.10 BioDiem
7.10.1 BDM-E: A High-Value Divestment?
7.11 Can-Fite BioPharma/OphthaliX
7.12 Chengdu Kanghong Pharmaceutical
7.13 Eleven Biotherapeutics
7.14 EyeGate Pharmaceuticals
7.15 Gene Signal
7.15.1 Aganirsen: Preventing Corneal Graft Rejection
7.16 GSK
7.16.1 Darapladib for Diabetic Macular Oedema
7.17 Icon Bioscience
7.18 Lpath
7.18.1 iSONEP: Antibodies Against Bioactive Lipids
7.19 MacuCLEAR
7.19.1 MC 1101: a Potential Therapy for Dry AMD
7.20 Neurotech
7.20.1 Renexus (NT 501) for Dry AMD
7.21 Omeros
7.22 Ophthotech
7.22.1 Will Roche Succeed in Acquiring Fovista?
7.22.2 Fovista: Significant Improvement on Lucentis in Phase 2 Trials
7.22.3 Zimura: Complement C5 Inhibitor
7.23 Otsuka Pharmaceutical
7.24 OXiGENE: Developing Zybrestat for Wet AMD
7.25 RXi Pharmaceuticals: Will Bevasiranib Resume Development?
7.26 Shire
7.26.1 Lifitegrast (SHP606) for Dry Eye
7.26.2 Premiplex (SHP607): Preventing Retinopathy of Prematurity
7.27 ThromboGenics
7.27.1 Jetrea (ocriplasmin)
7.27.1.1 Jetrea: US Sales Forecast 2015-2025
7.27.2 TB 403: Anti-Placental Growth Factor
8. Qualitative Analysis of the Ophthalmic Drugs Market 2015-2025
8.1 Porter’s Five Forces Analysis of the Ophthalmic Drugs Market
8.1.1 Rivalry Among Competitors [Medium]
8.1.2 Threat of New Entrants [Low]
8.1.3 Power of Suppliers [Low]
8.1.4 Power of Buyers [Medium]
8.1.5 Threat of Substitutes [Medium]
9. Research Interviews
9.1 Interview with Dan Myers, President and CEO, Alimera Sciences
9.1.1 Alimera Sciences’ Key Products
9.1.2 Expectations for the Launch of Iluvien in the US and EU
9.1.3 Alimera Sciences’ Plans for Growth
9.1.4 Alimera Sciences’ Ophthalmic Pipelines
9.1.5 Challenges in the Ophthalmic Drugs Market
9.1.6 Treatment Change in Retinal Disorders in the Next Decade
9.1.7 Successful Therapies in Ophthalmology in the Next Decade
9.1.8 Trends and Developments in the Ophthalmic Drugs Market
9.2 Interview with Dr. Leigh Hsu, Vice President, Corporate Development and Strategy, Lpath Inc.
9.2.1 Lpath’s Work in Ophthalmology
9.2.2 Progress Update on iSONEP in Clinical Development
9.2.3 Planned Phase 3 Trials in 2015?
9.2.4 Lpath’s Plans for Growth
9.2.5 Main Unmet Needs in Ophthalmology
9.2.6 Promising New Drug Targets in Development
9.2.7 Potential Treatments for Retinal Disorders in the Next Decade
9.2.8 Trends in Ophthalmology: Combination Therapy, Implants, Delivery Methods
9.3 Interview with a Spokesperson for Vanda Pharmaceuticals, Washington DC, US
9.3.1 Commercialising Hetlioz
9.3.2 Future Prospects for Vanda
10. Conclusions
10.1 Ophthalmic Pharmaceuticals: A Growing Niche Market
10.2 The World Ophthalmic Drugs Market in 2014
10.2.1 Leading Ophthalmic Drugs Market Segments
10.2.2 Leading Ophthalmic Drugs
10.2.3 Leading Ophthalmic Drugs Companies
10.3 World Ophthalmic Drugs Market Forecast 2015-2025
10.4 The Future of the Ophthalmic Drugs Market?
10.4.1 Increasing Revenue Concentration among Specialist Companies
10.4.2 The Rise of Generics
10.4.3 Small Companies Can Have a Big Impact
10.4.4 What Will Succeed in the Ophthalmic Drugs Market?
11. Glossary
【レポート販売概要】
■ タイトル：世界の眼疾患治療薬分野における主要な製薬企業分析■ 英文：Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025
■ 発行日：2015年2月
■ 調査会社：visiongain
■ 商品コード：VGAIN503041
■ 調査対象地域：グローバル
- 耐放射線型エレクトロニクスの世界市場予測（～2022年）：パワーマネジメント、ASIC、ロジック、メモリ、FPGAThe radiation-hardened electronics market was valued at USD 935.9 Million in 2015 and is expected to reach USD 1,277.4 Million by 2022, at a CAGR of 4.46% during the forecast period. The growth of this market is being propelled by the increased global intelligence, surveillance, & reconnaissance (ISR) operations around the globe, advancements in FPGA & multicore processor technologies for defense …
- スマートトイ（玩具）の世界市場2019-2023106 Pages, November 2018 About this market Consumers are able to attain their own 3D prints of their favorite toy characters from the comforts of their homes. 3D printing help pirate toy vendors to replicate original toys and sell them at lower prices. Technavio’s analysts have predicted that the global smart toys market will register a CAGR of almost 5% by 2023. Market overview Adoption of STEM t …
- 自動車用燃料デリバリーシステムの世界市場展望2017-2026According to Stratistics MRC, the Global Automotive Fuel Delivery System Market is accounted for $14.86 billion in 2017 and is expected to reach $27.18 billion by 2026 growing at a CAGR of 6.9%. Rising sales of passenger cars globally, penetration of new fuels and technological advancements are some of the key driving factors for the market growth. However, the efficient and sophisticated fuel del …
- 拡張現実および仮想現実の世界市場2015-2022According to Sratistics MRC the global augmented and Virtual Reality market is accounted for $2.67 billion in 2015 and is estimated to reach $66.68 billion by 2022, at a CAGR of 58.3%. The market is mostly motivated by software applications and hardware devices for 3D visualization. This particular technology is used in a wide range of applications such as entertainment, gaming and for training pu …
- パーティクルカウンターの世界市場予測（～2021年）：大気粒子カウンター、液体粒子カウンターThe particle counters market is projected to reach USD 330.6 million by 2021 from USD 275.9 million in 2016, at a CAGR of 3.7%. The growing pharmaceutical and semiconductor industries, increasing spending on pharmaceutical R&D, and growth in manufacturing industries in emerging nations are key factors driving the market growth for particle counters. On the other hand, technical limitations of part …
- 集光型太陽光発電の世界市場：放物面トラフ、太陽光発電タワー、フレネル反射器、皿スターリングThe global concentrated solar power market was valued at $ 3,793.0 million in 2018 and is projected to reach $ 8,046.7 million by 2026, growing at a CAGR of 10.3% from 2019 to 2026. The MEA region accounted for nearly 21.0% market share in 2018. CSP utilizes mirror configurations to concentrate the solar light energy onto a receiver. It then converts the energy into heat, which can be used further …
- レーダーセキュリティの世界市場：地上監視レーダー（GSR）、対空監視レーダー（ASR）、海上監視レーダー（MSR）The radar security market is in the growth phase. The said market is expected to grow from USD 17.85 Billion in 2016 to USD 25.17 Billion by 2022, at a CAGR of 5.90% between 2016 and 2022. The rising demand for radar systems worldwide since militaries seek to replace legacy systems. Rising territorial conflicts and geopolitical instabilities in the Middle East and Asia-Pacific regions is also a ke …
- フランスの血液凝固検査市場2014This report provides an overview of the French coagulation testing market, including sales and market shares of leading reagent and instrument suppliers, as well as test volume and sales forecasts by market segment.Table of ContentsBusiness Environment Market Structure Market Size, Growth, and Major Sup …
- 世界の心臓安全サービス市場：種類別（スタンドアロン、統合）、サービス別（ECG /ホルター測定、血圧、心臓イメージング、徹底QT研究、その他のサービス）、エンドユーザー別（医薬品およびバイオ医薬品会社、CRO）“The cardiac safety services market is projected to register a CAGR of 11.2% during the forecast period.” The cardiac safety services market is projected to reach USD 752 million by 2024 from USD 442 million in 2019, at a CAGR of 11.2%. Growth in this industry is driven by the growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, increased outsourcing of R&D activities, and t …
- Workspace-as-a-Service（WaaS）ベンダー比較Workspace-as-a-Service (WaaS) is a blend of unified managed services delivered to enhance and automate the delivery of applications and data across multiple personalized devices without threatening the security of the data or the device itself. Furthermore, increase in proliferation of portable devices in enterprise and dependency of enterprise class applications is driving the need for deployment …
- インテリジェントピギングの世界市場2019-2023About this market Several additional applications of intelligent pigging over traditional pigging are accelerating the market growth during the forecast period. Intelligent pigging provides accurate data about the condition of pipelines. Furthermore, it provides numerous advantages due to the increasing use of several methods to perform inspection and cleaning simultaneously, while saving money an …
- 酢酸ナトリウムの世界市場2018-2022About Sodium Acetate Sodium acetate, also known as sodium ethanoate, is the trihydrate sodium salt of acetic acid. Sodium acetate is synthesized by reacting acetic acid with sodium hydroxide or sodium carbonate. Based on its formation, sodium acetate occurs in two forms—the crystal form called sodium acetate trihydrate (SAT) and the anhydrous form called sodium acetate anhydrous (SAA). Technavio’s …
- 3G<E上のモバイルセキュリティー及びプライバシー：戦略、ソリューション、予測（Mobile Security and Privacy in 3G & LTE: Strategies, Solutions and Market Forecast Analysis 2012-2017）This market has been initially driven by business concerns about protection of corporate assets and information. Mobile threats are becoming increasingly prolific as the mobile platform continues to gain popularity through the adoption of smart devices. As end-users and businesses come to rely on smartphones and tablets in their personal and business activities, they store valuable information tha …
- オンラインギャンブルの世界市場2015-2019About online gambling Online gambling includes betting, gaming, and lottery through smartphones, tablets, PCs, and laptops by using the Internet. The revenue generated through betting includes the wagers put on outdoor sports such as football, tennis, cricket, basketball, and horse racing. Revenue from gaming includes money spent on casino games and slot machines. Lottery generates revenue from ga …
- 運輸業におけるGISの世界市場2016-2020：GISソフトウェア、GISデータ、GISサービスAbout GIS GIS is a set of tools used to interpret business and geospatial data. It integrates hardware, software, data, and services for processing businesses and geographically referenced data. This system digitizes the received geospatial data and processes them to provide the desired output. Sectors such as national government, transportation, natural resources, military/law enforcement, utilit …
